Hemangioma

Order, Stanley E.; Donaldson, Sarah S.

doi:10.1007/978-3-642-58719-1_51

Cited by 1 publication

(1 citation statement)

References 58 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Given that the success rate of radiation therapy for preventing recurrence of these lesions is modest and that the potential neurocognitive effects of radiation to the temporal lobe are significant, 14 the recommendation was made to undertake treatment with the vascular endothelial growth factor inhibitor bevacizumab and the alkylating agent temozolomide in an attempt to shrink the tumor and delay or avoid radiation therapy. It was hoped that should radiotherapy become necessary, a more limited field could be achieved by reducing the tumor volume.…”

Section: Division Of Oncology Children's National Medical Center Wamentioning

confidence: 99%

Durable response of intracranial cellular hemangioma to bevacizumab and temozolomide

Yeo

Puscasiu²,

Keating

et al. 2013

PED

View full text Add to dashboard Cite

Cellular hemangioma is a subtype of hemangioma that is associated with cellular immaturity and the potential for recurrence. Intracranial location of these lesions is extremely rare, and definitive treatment often requires radical neurosurgical resection. The authors report a case of a 12-year-old boy with a subtemporal cellular hemangioma. He underwent gross-total resection of the tumor, but within 1.5 months the tumor recurred, necessitating a second resection. Because of its proximity to vascular structures, only subtotal resection was possible. Repeat MRI 1 month after the second surgery showed significant tumor recurrence. Given the tumor's demonstrated capacity for recurrence and its proximity to the vein of Labbé and sigmoid sinus, further resection was not indicated. In an effort to limit radiation therapy for this young patient, treatment with bevacizumab and temozolomide was chosen and achieved a complete response that has proven durable for 36 months after cessation of therapy. This is the first report of the successful use of chemotherapy to treat an intracranial hemangioma, a rare condition with limited therapeutic options.

show abstract

Section: Division Of Oncology Children's National Medical Center Wamentioning

confidence: 99%